Y-mAbs Therapeutics: The Final Chapter for Independent Trading

The independent market journey for Y-mAbs Therapeutics has reached its conclusion following the company's acquisition by SERB Pharmaceuticals. This transformative $412 million transaction was finalized by the French pharmaceutical giant on September 16, 2025, marking the end of the biotech firm's standalone equity story.

Trading activity for Y-mAbs shares displayed clear signals of impending delisting in the final sessions. On the last trading day, October 23, 2025, the stock price remained static at $8.61, showing absolutely no fluctuation between daily highs and lows. The security had exhibited zero volatility throughout the preceding two weeks—a definitive indicator of winding-down market operations.

Market monitoring service MarketBeat has already flagged the company as "potentially delisted," cautioning investors about potentially inactive trading conditions. The unusual silence across trading platforms speaks volumes about a stock preparing for its market exit.

Widespread Analyst Pessimism Preceded Acquisition

Market experts had maintained a negative outlook on Y-mAbs even before the acquisition announcement. The consensus rating stood at "Reduce," supported by an average score of just 1.80 points. Within a 90-week period, six separate analysts had downgraded their assessments of the company.

Should investors sell immediately? Or is it worth buying Y-mAbs Therapeutics?

The final remaining price targets revealed extreme divergence among researchers:
* Average twelve-month target: $9.62
* Target range spanning $3.00 to $17.00
* Negative earnings per share of ($0.65)

When measured against other medical technology companies, which typically maintained "Hold" ratings, Y-mAbs consistently underperformed in analyst evaluations.

The New Reality for Shareholders

SERB Pharmaceuticals' acquisition has rendered traditional equity analysis irrelevant for Y-mAbs. Price targets, earnings projections, and independent valuations now belong to history. The future trajectory of this former biotech contender rests entirely with its new corporate parent.

For existing shareholders, this development closes the book on Y-mAbs as an independent investment narrative. What remains is the company's integration into a larger pharmaceutical enterprise and the memory of a stock that surrendered its autonomous market status.